G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 2 079.8 INR -1.58% Market Closed
Market Cap: 586.9B INR

Net Margin
Glenmark Pharmaceuticals Ltd

6.3%
Current
1%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.3%
=
Net Income
10.1B
/
Revenue
159.6B

Net Margin Across Competitors

No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.

GLENMARK Intrinsic Value
1 565.69 INR
Overvaluation 25%
Intrinsic Value
Price
G
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.3%
=
Net Income
10.1B
/
Revenue
159.6B
What is the Net Margin of Glenmark Pharmaceuticals Ltd?

Based on Glenmark Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of 6.3%.

Back to Top